title: Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.
abstract: BACKGROUND
  Knowledge of the number of persons with chronic hepatitis C virus (HCV) infection in the United States is critical for public health and policy planning.
  
  
  OBJECTIVE
  To estimate the prevalence of chronic HCV infection between 2003 and 2010 and to identify factors associated with this condition.
  
  
  METHODS
  Nationally representative household survey.
  
  
  METHODS
  U.S. noninstitutionalized civilian population.
  
  
  METHODS
  30,074 NHANES (National Health and Nutrition Examination Survey) participants between 2003 and 2010.
  
  
  METHODS
  Interviews to ascertain demographic characteristics and possible risks and exposures for HCV infection. Serum samples from participants aged 6 years or older were tested for antibody to HCV; if results were positive or indeterminate, the samples were tested for HCV RNA, which indicates current chronic infection.
  
  
  RESULTS
  Based on 273 participants who tested positive for HCV RNA, the estimated prevalence of HCV infection was 1.0% (95% CI, 0.8% to 1.2%), corresponding to 2.7 million chronically infected persons (CI, 2.2 to 3.2 million persons) in the U.S. noninstitutionalized civilian population. Infected persons were more likely to be aged 40 to 59 years, male, and non-Hispanic black and to have less education and lower family income. Factors significantly associated with chronic HCV infection were illicit drug use (including injection drugs) and receipt of a blood transfusion before 1992; 49% of persons with HCV infection did not report either risk factor.
  
  
  CONCLUSIONS
  Incarcerated and homeless persons were not surveyed.
  
  
  CONCLUSIONS
  This analysis estimated that approximately 2.7 million U.S. residents in the population sampled by NHANES have chronic HCV infection, about 500,000 fewer than estimated in a similar analysis between 1999 and 2002. These data underscore the urgency of identifying the millions of persons who remain infected and linking them to appropriate care and treatment.
  
  
  BACKGROUND
  None.
authors.forename: Maxine M
authors.initials: MM
authors.lastname: Denniston
authors.forename: Ruth B
authors.initials: RB
authors.lastname: Jiles
authors.forename: Jan
authors.initials: J
authors.lastname: Drobeniuc
authors.forename: R Monina
authors.initials: RM
authors.lastname: Klevens
authors.forename: John W
authors.initials: JW
authors.lastname: Ward
authors.forename: Geraldine M
authors.initials: GM
authors.lastname: McQuillan
authors.forename: Scott D
authors.initials: SD
authors.lastname: Holmberg
mesh_terms: D000328:Adult; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009749:Nutrition Surveys; D015995:Prevalence; D012367:RNA, Viral / Q000032:analysis; D012307:Risk Factors; D019966:Substance-Related Disorders / Q000150:complications; D065227:Transfusion Reaction; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral
references.citation: Hepatology. 2010 Oct;52(4):1497-505
references.pmid: 20635398
references.citation: Gen Hosp Psychiatry. 2013 Mar-Apr;35(2):122-8
references.pmid: 23219917
references.citation: Clin Infect Dis. 2014 Apr;58(8):1055-61
references.pmid: 24523214
references.citation: J Infect Dis. 2004 Sep 15;190(6):1059-67
references.pmid: 15319854
references.citation: JAMA. 2001 Jun 27;285(24):3100-6
references.pmid: 11427138
references.citation: Clin Infect Dis. 2012 Oct;55(8):1047-55
references.pmid: 22875876
references.citation: Ann Intern Med. 2006 May 16;144(10):705-14
references.pmid: 16702586
references.citation: Ann Intern Med. 2012 Dec 4;157(11):817-22
references.pmid: 22910836
references.citation: Hepatology. 2005 Dec;42(6):1406-13
references.pmid: 16317670
references.citation: Hepatology. 2012 Jun;55(6):1652-61
references.pmid: 22213025
references.citation: Lancet. 2012 Dec 15;380(9859):2095-128
references.pmid: 23245604
references.citation: Ann Intern Med. 2012 Feb 21;156(4):271-8
references.pmid: 22351712
references.citation: N Engl J Med. 2013 May 16;368(20):1859-61
references.pmid: 23675657
references.citation: N Engl J Med. 2013 Jan 3;368(1):45-53
references.pmid: 23281975
references.citation: J Viral Hepat. 2013 Sep;20(9):628-37
references.pmid: 23910647
references.citation: MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32
references.pmid: 22895429
references.citation: Clin Infect Dis. 2011 Jul 15;53(2):150-7
references.pmid: 21665867
references.citation: N Engl J Med. 1999 Aug 19;341(8):556-62
references.pmid: 10451460
references.citation: Clin Infect Dis. 2012 Jul;55 Suppl 1:S16-24
references.pmid: 22715209